SM-020 / DermBiont - LARVOL DELTA

A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: DermBiont, Inc. | Active, not recruiting ➔ Recruiting | Trial primary completion date: Jun 2024 ➔ Sep 2024

Enrollment open • Trial primary completion date

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: DermBiont, Inc.

New P2 trial • Basal Cell Carcinoma • Bowens Disease • Genetic Disorders • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Skin Nodular Basal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN) (clinicaltrials.gov) - P2 | N=10 | Active, not recruiting | Sponsor: DermBiont, Inc. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Mar 2024 ➔ Jul 2024

Enrollment closed • Trial primary completion date • Dermatology

A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: DermBiont, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed

DermBiont Announces 2024 Development Pipeline Update for its First-in-Class Targeted Topical Therapeutics for Seborrheic Keratoses, Basal Cell Carcinomas, and Melasma (Businesswire) - "...DermBiont is initiating a Phase 2a (CT-217) open-label trial in up to 40 subjects with one to five basal cell carcinomas (BCC) or squamous cell carcinoma in situ (SCCIS). This open label trial’s primary endpoints are the reduction in greatest tumor diameter at week 6 compared to baseline, and the safety of drug product for BCCs or SCCISs based on application site reactions. Secondary endpoints include the percentage of BCCs or SCCISs that achieve histologic cure at week 6...Upcoming Milestones....BCCs and SCCISs: DermBiont expects to initiate its CT-217 Phase 2a clinical trial in Q1 2024 and report data in Q3 2024."

New P2a trial • P2a data • Basal Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor

A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: DermBiont, Inc.

New P2 trial

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN) (clinicaltrials.gov) - P2 | N=10 | Recruiting | Sponsor: DermBiont, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN) (clinicaltrials.gov) - P2 | N=10 | Not yet recruiting | Sponsor: DermBiont, Inc.

New P2 trial • Dermatology

Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: DermBiont, Inc. | N=35 ➔ 70 | Trial completion date: Jun 2023 ➔ Jul 2024 | Trial primary completion date: Mar 2023 ➔ May 2024

Enrollment change • Trial completion date • Trial primary completion date

Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis (clinicaltrials.gov) - P2 | N=35 | Active, not recruiting | Sponsor: DermBiont, Inc. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Dec 2022 ➔ Mar 2023

Enrollment closed • Trial primary completion date

Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: DermBiont, Inc. | Trial completion date: Jun 2022 ➔ Jun 2023 | Trial primary completion date: Mar 2022 ➔ Dec 2022

Trial completion date • Trial primary completion date